Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), September 2008
First Received: November 22, 2005   Last Updated: September 29, 2008   History of Changes
Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00258479
  Purpose

Nicotine is one of the most widely abused substances in the United States. Nicotine replacement therapy (NRT) is currently an effective treatment for nicotine dependence; however, even with NRT most people fail at quitting smoking after their first attempt. Modafinil is a promising drug that may be useful in treating nicotine dependent individuals. The purpose of this study is to evaluate the safety of the combination of modafinil and NRT in treating nicotine dependent adolescent smokers.


Condition Intervention Phase
Tobacco Use Disorder
Drug: Modafinil
Drug: Nicotine Replacement Therapy
Phase I

Drug Information available for: Nicotine tartrate Modafinil Nicotine polacrilex
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Safety Study
Official Title: Modafinil and Nicotine in Adolescents: Phase I Trial

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Safety of combination drug treatment and physiological response; measured after treatment with each dose combination [ Time Frame: laboratory session ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: June 2003
Estimated Study Completion Date: March 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Modafinil
    A dose escalation design for all subjects includes eight dose conditions tested across a 12-day study (nicotine low and high, modafinil low and high and 4 combinations). After day 1 placebo dose, placebo sessions will occur in random order during 1) low dose testing, 2) high dose testing, and 3) dose-combination testing. Modafinil and nicotine will each be tested alone, with participants exposed to low active doses prior to higher doses. Dose interactions will then be determined, with low doses of each drug tested in combination followed by low-high dose combinations, prior to the high-high dose combination. All doses will be administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) will be applied at 7 am on the morning of test. Modafinil doses will be prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) will be administered at 5 PM.
    Drug: Nicotine Replacement Therapy
    See Modafinil Intervention Description above.
Detailed Description:

NRT is a critical part of treating nicotine withdrawal symptoms, such as cravings, sleeplessness, poor concentration, and anxiety. The addition of modafinil, a promising pharmacologic agent, may enhance the effectiveness of NRT by further reducing inattention and depressed mood. The purpose of this study is to examine the safety of using both modafinil and NRT in treating nicotine dependent adolescents. In addition, this study will examine the effects of modafinil and NRT, alone and in combination, on alleviating symptoms of inattention and depressed mood.

Participants in this 12-day dose escalation study will be tested under eight different dose conditions. Modafinil and NRT will first be tested alone; participants will be exposed to low doses prior to higher doses of medication. Various modafinil-NRT dose combinations will then be tested. Modafinil will be administered at 5 p.m. each day, and NRT will be self-administered at the start of each day in which a participant must complete lab tests. The following measures will be obtained at study visits occurring before and after the various modafinil-NRT dose combinations: nicotine withdrawal symptoms, medication side effects, activity level, cardiovascular response, and profile of mood states (POMS).

  Eligibility

Ages Eligible for Study:   16 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Smokes 10 or more cigarettes per day

Exclusion Criteria:

  • Current use of any medication for a psychiatric disorder
  • Positive drug screen test
  • Uses smokeless tobacco
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00258479

Contacts
Contact: Catherine A. Martin, MD 859-257-9341 cmartin@uky.edu

Locations
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40509
Contact: Catherine Martin, MD     859-257-9341     cmartin@uky.edu    
Principal Investigator: Catherine A. Martin, MD            
Sponsors and Collaborators
Investigators
Study Chair: Catherine Martin, PhD University of Kentucky
  More Information

No publications provided

Responsible Party: University of Kentucky ( Catherine A. Martin )
Study ID Numbers: NIDA-15413, R03DA15413, DPMC
Study First Received: November 22, 2005
Last Updated: September 29, 2008
ClinicalTrials.gov Identifier: NCT00258479     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):
Nicotine Dependence
Nicotine Use Disorder
Tobacco Dependence

Study placed in the following topic categories:
Nicotine polacrilex
Neurotransmitter Agents
Tobacco Use Disorder
Nicotinic Agonists
Disorders of Environmental Origin
Central Nervous System Stimulants
Cholinergic Agents
Neuroprotective Agents
Modafinil
Mental Disorders
Nicotine
Substance-Related Disorders
Peripheral Nervous System Agents

Additional relevant MeSH terms:
Nicotine polacrilex
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Tobacco Use Disorder
Nicotinic Agonists
Physiological Effects of Drugs
Disorders of Environmental Origin
Central Nervous System Stimulants
Cholinergic Agents
Protective Agents
Neuroprotective Agents
Modafinil
Pharmacologic Actions
Mental Disorders
Nicotine
Autonomic Agents
Therapeutic Uses
Substance-Related Disorders
Ganglionic Stimulants
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009